The companies will perform tumor profiling to identify patients with genetic abnormalities that could make them eligible for treatment in the NCI study.
There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.
Though considered potential antibody alternatives, these reagents are more likely to succeed in new applications for which conventional tools are poorly suited.
There was a lot of growth in the precision medicine field in the past year, and some experts believe the FDA's decision to hold off on regulating LDTs could spur more innovation.
